6th AMR Conference
AMR Conference
AMR Conference
AMR Conference
SAVE THE DATE for the
6th AMR Conference 2022
We are pleased to announce that our 6th AMR Conference 2022 will be organized as a face-to-face event. We are looking forward to meet each other in person from
7–8 April 2022
Sign up for our newsletter to stay informed about all further plannings regularly.
Latest News
in the AMR and antimicrobial space
BEAM Alliance is among the partners of AMR-focused incubator INCATE. We spoke with Marc Gitzinger, CEO…
The Boehringer Ingelheim Venture Fund is among the industry partners of AMR-focused incubator INCATE. We spoke…
The Japanese pharma company Shionogi is among the industry partners of AMR-focused incubator INCATE. We spoke…
BioNTech SE has acquired PhagoMed GmbH, an Austrian start-up for precision antimicrobial treatments supported by the…
Vaccines and monoclonal antibodies (mAb) (molecules engineered to mimic the immune response towards harmful pathogens) can…
Antibiotic Research UK (ANTRUK) announced that through its 2021 Small Research Grants / Career Development Awards…
AMR experts from Industry, SMEs, academia and public bodies discussed the impact of COVID-19 on AMR…
Investment climate for companies active in AMR was rather weak for a long time. However, over…
During the third day of the virtual 5th AMR Conference, the important role of governments and…
6th AMR Conference – What you can expect
The AMR Conference is a platform to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to market.
More than 400 delegates from 25+ countries
80+ high-level speakers in 20 sessions
Pre-conference workshops and satellite meetings
A variety of topics from R&D to financing, regulation & incentives
Poster session, exhibition and pre-scheduled 1:1 partnering meetings
SMEs, academics & governmental agencies benefit from discounted fees
Supporting Partners of the 5th AMR Conference
2021 Event Highlights
Summer Edition – AMR Briefing Sessions
With around 30 international experts in the line-up, the virtual conference discussed the current state of the fight against antimicrobial resistance (AMR) during three Briefing sessions, which took place from 24 to 26 August under the umbrella of the 5th AMR Conference – Summer Edition.
Almost 500 registered participants took part in the event to follow discussions about pandemic preparedness, the COVID-19 impact on AMR R&D, the financing climate and policy incentives.
Overall, most of the stakeholders emphasised that there is a momentum of optimism. “The level of investment is rising, interest in the field has improved and the overall trend is quite good. Particularly vaccines have found investments”, said Aleks Engel from Novo Holdings REPAIR Impact Fund. Overall, Engel also underlined that there is a lot of innovation taking place in the AMR field: “When we started our fund three years ago, we were embarrassed to see how many innovative companies there are, many more than we could invest in with our fund.” In the meantime, many of them have developed further.
2020 Event Highlights
Event Impressions & Testimonials
The #AMRconference 2020 was a great success. Almost 450 international AMR experts have participated in 26 live sessions which provided a 360 degree overview of the current AMR industry and resulted in engaging discussions.
Did you miss the conference?
Purchase our on-demand license and watch all 20+ sessions and panel discussions whenever you want!
Get your individual licence to access all session recordings, slides and scientific poster presentations of the AMR Conference 2020 here:
2019 Event Highlights
Event Impressions & Testimonials
More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). The AMR Conference is a platform for SMEs, start-ups, big pharma, academia, clinicians, investors, public stakeholders and policy-makers to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.
